The U.S. Supreme Court in Shute v. Carnival Cruise Lines, 499 U.S. 585 (1991) held the Shutes, who were injured on a Carnival Cruise ship in waters off Mexico, must file suit in Florida pursuant to the forum selection provision printed on the back of their ticket.   The Shutes filed suit in their home state of Washington.  The cruise ship departed from California.  Shute is still one of the most far reaching holdings enforcing adhesion-like forum selection provisions.  The Shutes also had a strong argument that they lacked notice of the forum selection/choice of law provisions.  

In the recent running aground of the Italian Costa Concordia operated by Costa Crocier, which is controlled by Carnival, the ship departed near Rome.  Approximately 120 United States citizens were on board and two may still be missing.  With respect to notice of the forum selection and choice of law provisions, information is much easier to obtain now than it was when Shute was decided.  For example, Carnival now posts its ticket contract online.  Carnival’s contract includes a mandatory arbitration provision as well as a forum selection clause, limits on liability, and restricted statute of limitations periods.   Costa Crocier also posts their ticket contract online.  The Costa contract includes forum selection, arbitration and choice of law provisions at Section 2.    

For claims involving personal injury or death, the Costa contract includes a forum selection clause for Broward County, Florida for cruises that depart from, visit or return to a U.S. port.  In contrast, U.S. port related economic loss claims are subject to an arbitration provision.  Under the Costa contract, any cruise that does not depart from, visit or return to a U.S. port, all claims must be filed in Genoa, Italy, and Italian law applies.  The Costa contract also includes a jury waiver provision.  

When a district court applies a forum selection provision, it usually does so via 28 U.S.C. § 1404, whereas a state court would dismiss the case.  Italy is not a district to which a federal case can be transferred, so dismissal is likely remedy if court enforces forum selection provisions for U.S. citizen cases filed in their home state, or even in Florida.  See e.g., Albemarle Corp. v. Astrazeneca U.K, Ltd., 628 F.3d 643, 651 (4th Cir. 2010) (applying English law / federal common law to enforce forum selection clause via dismissal).  Albemarle also suggests that Costa Concordia related claims filed in the U.S. would still be analyzed under the four factor “unreasonableness” test set forth in M/S Bremen v. Zapata Off–Shore Co., 407 U.S. 1 (1972) (holding forum selection clause may be found unreasonable if “(1) [its] formation was induced by fraud or over-reaching; (2) the complaining party ‘will for all practical purposes be deprived of his day in court’ because of the grave inconvenience or un-fairness of the selected forum; (3) the fundamental unfairness of the chosen law may deprive the plaintiff of a remedy; or (4) [its] enforcement would contravene a strong public policy of the forum state.”).     

Here, proponents of avoiding Costa Crocier’s forum selection clause and choice of Italian law may argue factors two, three and four.  An analysis of Italian law related to factor three is beyond the scope of this blog post!
Bookmark and Share

 

 

Law.com has an interesting blog post about a recent defense tactic in the case of an alleged “mouse in a can of soda,” you can find the article here. Basically, the defendant is taking a scientific stand regarding the presence of a mouse allegedly sealed in a can of soda. Essentially, they are saying that a whole mouse would not be present in a sealed can, because the acid in the drink would have turned it to jelly. The beverage giant  may need to start competing with jelly and jam companies.  The position may be technically viable but it appears be a public relations nightmare. Do you think this is an effective stance? Does it do more harm than good? Let us know your thoughts.

Jobby is an associate in the Oklahoma City firm of Hiltgen & Brewer, P.C.  

Bookmark and Share

 

The new IOM report, Breast Cancer and the Environment: A Life Course Approach, again emphasizes the difference between how scientific panels go about making a causal inference and the approach too often approved of by credulous judges often insecure about their own ability to think critically and mesmerized by the jargon-laden pronouncements of credentialed experts. Beginning on page 82 under "Hierarchy of Studies" and followed by "Categories of Evidence" the report does a great job of detailing what counts as evidence and the methods and criteria used by organizations like the International Agency for Research on Cancer, the National Toxicology Program, the World Cancer Research Fund / American Institute for Cancer Research in going about collecting, assessing and weighing evidence when making causal judgments. They even put together a helpful summary of the classification systems (see Appendix C, "Classifications Systems Used in Evidence Reviews" at page 312).

Here are a couple of takeaways:

(1) "The criteria aim to be explicit about the weight, or relative importance, given to studies in humans and in animals or other experimental systems"; and

(2) "Strong and consistent positive epidemiologic evidence in rigorously conducted studies is prima facie evidence that the substance is a risk factor." You will quickly note upon reviewing the summary of systems of causal inference that none support anything like the notion embraced by the court in Milward v. Acuity that an expert weighing a subset of the data (each piece of which is either weak, irrelevant or inconsistent) upon the scales of his personal scientific judgment can by "reasoning to the best explanation" reliably reach a causal inference  - especially in the complete absence of any epidemiological evidence to support it. Indeed the "atomization" of evidence decried by the Milward court and those in the "public health movement" who promote mass tort litigation is exactly what IARC, IOM, NTP, EPA and WCRF/AICR do - they assess each piece of evidence, they do it transparently, they do it according to rules laid down before they even go looking for the evidence and then they weigh what's left; again, according to weighting systems that are explicit, consistent and established before the first piece of evidence is examined.

The idea that knowledge comes from scientists taking a "holistic approach to the data" and applying their personal judgment to it is, to be blunt, hooey. That may be a way to arrive at a testable conjecture but without the conjecture passing a test of its predictive power (e.g. a rigorous epidemiological study) it remains nothing but a bald, personal opinion with no foundation beyond the ipse dixit of the expert who induced it.

 David Oliver is managing partner of the Houston office of Vorys, Sater, Seymour and Pease. His practice focuses on civil litigation involving allegations of injuries due to exposure to chemicals or pharmaceuticals; he holds degrees in both chemistry and biology. Read more of David’s work on his blog: Mass Torts: State of the Art. You may contact David through the firm’s website at www.vorys.com.

Bookmark and Share

 

The Consumer Product Safety Commission (CPSC) recently adopted a rule that requires children's products (products used by children twelve and under) to be tested by an authorized and independent third-party.  On October 19, 2011, the CPSC voted 3-2 along party lines to pass the rule.  The rule will likely take effect February 2013. 

Before this rule, it was the manufacturer's responsibility to test its products and ensure that they met all safety requirements before releasing them into the stream of commerce.  But by passing this rule, three CPSC Commissioners obviously felt that self-testing and market forces were insufficient to keep unsafe products away from children.  According to Chairman Inez Tenenbaum, the rule will fetter out unsafe children's products before they get in the hands of children.     

While consumer safety advocates see the rule as a much needed safety measure, manufacturers are not happy.  Not only will every new children's product have to be independently tested, but any design, manufacturing, or component change will require a product to be re-tested.  All of this testing will either require manufacturers to absorb extra costs, or pass them onto customers.  And in this economy, passing on costs to consumers can lead to fewer sales and hurt a manufacturer's bottom line. 

Whether or not the rule will actually improve the safety of children's products is yet to be determined.  But it is a foregone conclusion that manufacturers and consumers are footing the bill either way.    

 

William F. Auther is a partner with an active trial practice in product liability and business litigation and Kelly M. McInroy is an associate in the Phoenix office of Bowman and Brooke LLP.  

Bookmark and Share

 

 

Jamie Oliver, a chef and a child advocate focused on ensuring kids receive proper nutrition through their school lunch programs as well as at home, has a television show, Jamie Oliver’s Food Revolution, showing how he changes eating habits in school districts (this season he is in Los Angeles).  In each episode, he creates a visual showing the terrible foods kids are putting in their bodies.  It’s one thing to tell kids (or their parents) that fast food and processed food is bad for them, it is quite another to create a visual showing how bad it is, and creating such a powerful visual that it convinces those kids, their parents and the audience watching the show (including myself) how bad those foods are.  In a recent episode, he filled a family’s house with all the fast food they consume in a year.  Every square inch of furniture and floor was covered.  In another episode, he filled a school bus with sugar to show how much sugar the school board permitted in the kids lunch meals over a year.  It was powerful images like those that made folks change their minds and change their behavior.

When preparing for trial, we can take a page out of Jamie’s book, and think about what visuals (whether a photograph, a diagram, an animation, or some other representation) that encapsulates our theme and does so in such a powerful manner that the image we create carries through the trial, into the deliberation room and turns the jurors’ hearts and minds toward our view-point and toward our position.  Keep a file folder in your office drawer where you include pictures, images and ideas you clip from magazines and newspapers.  These images may later serve you at trial.

Being that it is Monday, my partner Craig Salner has his weekly tip for young lawyers.  This week he discusses the importance of getting involved with social networking.  You can find his post at http://csalner.wordpress.com/.

Bookmark and Share

 

Ad Age recently posted an article addressing the meteoric rise and overwhelming dominance of the smartphone.  At the end of this holiday season, over 50 percent of mobile phone users will be using a smartphone.  A year from now, that figure is projected to almost double, to 90 percent of mobile users.  Moreover, smartphone capabilities are growing almost as fast as their market saturation.  I regularly use my phone as a search tool, GPS, communications device (most of which centers on e-mail) and social hub, and I do not consider myself to be a “power user.”  Despite the amazing smartphone developments of the past 5 years, there are more on the horizon.  If the experts are right, we will soon be using our phones in place of our wallets, for identification and point of sale purchases.  Phones could be used to unlock and start our cars and to open our garage doors and set our home thermostats.  This week, conference attendees will be using the DRI smartphone App to keep track of their schedule and contact other attendees.  However, like most any “smart” device, the more we use our phones the more data we generate regarding our whereabouts, activities and lifestyles.

Attorneys used to subpoena cell phone records to see if litigants were on their phones at the time of an injury or during an auto accident.  Already, Historical Cellular Reconstruction (HCR) can be used to provide the history of a phone’s probable location, regardless of whether a user was actually on their phone.  HCR is not based on GPS data, but upon data and information maintained by the cellular provider related to a particular cell phone’s connection to a given cell tower.  Although HCR does not result in pinpoint precision, it can often place a phone within a very small vicinity.  If a user’s cell phone is turned on and the GPS is in operation, the precision increases dramatically.

Now attorneys look for information and material addressing whether a litigant was texting, surfing the web, on Facebook or taking one of virtually countless actions on their cell phones during the time of a given event, or in the hours and days leading up to a significant event.  Lawyers can use cell phone records to compare the location of a litigant to their claimed location.  This is particularly relevant where litigants, such as commercial drivers, are required to routinely log their position.  Records may indicate that an allegedly injured party went to an amusement park, or that an allegedly incapacitated person made a purchase.  The possibilities already seem endless, and as smartphone services continue to expand, so will the potential for using the resulting data in litigation.  As more and more opportunities are created by smartphone data, attorneys need to remain mindful of the fact that there may be data available that will impact their case.  

Bookmark and Share

 

In “RULE OF EVIDENCE 703 — Problem Child of Article VII (Sept. 19, 2011),” I wrote about how Federal Rule of Evidence 703 is generally ignored and misunderstood in current federal practice.  The Supreme Court, in deciding Daubert, shifted the focus to Rule 702, as the primary tool to deploy in admitting, as well as limiting and excluding, expert witness opinion testimony.  The Court’s decision, however, did not erase the need for an additional, independent rule to control the quality of inadmissible materials upon which expert witnesses rely.  Indeed, Rule 702 as amended in 2000, incorporated much of the learning of the Daubert decision, and then some, but it does not address the starting place of any scientific opinion:  the data, the analyses (usually statistical) of data, and the reasonableness of relying upon those data and analyses.  Instead, Rule 702 asks whether the proffered testimony is based upon:

1. sufficient facts or data,
2. the product of reliable principles and methods, and
3. a reliable application of principles and methods to the facts of the case

Noticeably absent from Rule 702, in its current form, is any directive to determine whether the proffered expert witness opinion is based upon facts or data of the sort upon which experts in the pertinent field would reasonably rely.  Furthermore,  Daubert did not address the fulsome importation and disclosure of untrustworthy hearsay opinions through Rule 703.  See Problem Child (discussing the courts’ failure to appreciate the structure of peer-reviewed articles, and the need to ignore the discussion and introduction sections of such articles as often containing speculative opinions and comments).  See also Luciana B. Sollaci & Mauricio G. Pereira, “The introduction, methods, results, and discussion (IMRAD) structure: a fifty-year survey,” 92 J. Med. Libr. Ass’n 364 (2004); Montori, et al., “Users’ guide to detecting misleading claims in clinical research reports,” 329 Br. Med. J. 1093, 1093 (2004) (advising readers on how to avoid being misled by published literature, and counseling readers to “Read only the Methods and Results sections; bypass the Discuss section.”)  (emphasis added).

Given this background, it is disappointing but not surprising that the new Reference Manual on Scientific Evidence severely slights Rule 703.  Using either a word search in the PDF version or the index at end of book tells the story:  There are five references to Rule 703 in the entire RMSE!  The statistics chapter has an appropriate but fleeting reference:

“Or the study might rest on data of the type not reasonably relied on by statisticians or substantive experts and hence run afoul of Federal Rule of Evidence 703. Often, however, the battle over statistical evidence concerns weight or sufficiency rather than admissibility.”

RMSE 3d at 214. At least this chapter acknowledges, however briefly, the potential problem that Rule 703 poses for expert witnesses.  The chapter on survey research similarly discusses how the data collected in a survey may “run afoul” of Rule 703.  RMSE 3d at 361, 363-364.

The chapter on epidemiology takes a different approach by interpreting Rule 703 as a rule of admissibility of evidence:

“An epidemiologic study that is sufficiently rigorous to justify a conclusion that it is scientifically valid should be admissible,184 as it tends to make an issue in dispute more or less likely.185"

Id. at 610.  This view is mistaken.  Sufficient rigor in an epidemiologic study is certainly needed for reliance by an expert witness, but such rigor does not make the study itself admissible; the rigor simply permits the expert witness to rely upon a study that is typically several layers of inadmissible hearsay.  See “Reference Manual on Scientific Evidence v3.0 – Disregarding Study Validity in Favor of the “Whole Gamish” (Oct. 14, 2011) (discussing the argument put forward by the epidemiology chapter for considering Rule 703 as an exception to the rule against hearsay).

While the treatment of Rule 703 in the epidemiology chapter is troubling, the introductory chapter on the admissibility of expert witness opinion testimony by the late Professor Margaret Berger really sets the tone and approach for the entire volume. See Berger, “The Admissibility of Expert Testimony,” RSME 3d 11 (2011).  Professor Berger never mentions Rule 703 at all!  Gone and forgotten. The omission is not, however, an oversight.  Rule 703, with its requirement of qualifying each study relied upon as having been “reasonably relied upon,” as measured by what experts in the appropriate discipline, is the refutation of Berger’s argument that somehow a pile of weak, flawed studies, taken together can yield a scientifically reliable conclusion. See “Whole Gamish,” (Oct. 14th, 2011).

Rule 703 is not merely an invitation to trial judges; it is a requirement to look at the discrete studies relied upon to determine whether the building blocks are sound.  Only then can the methods and procedures of science begin to analyze the entire evidentiary display to yield reliable scientific opinions and conclusions.


The author, Nathan A. Schachtman, is in private practice in New York City, and is a lecturer-in-law at the Columbia Law School.  He keeps a web log of musings on tort and evidence law at his website: schachtmanlaw.com

Bookmark and Share

 

(originally posted at Tortini <http://schachtmanlaw.com/reference-manual-on-scientific-evidence-v3-0-disregarding-study-validity-in-favor-of-the-whole-gamish/> on October 14, 2011.)

There is much to digest in the new Reference Manual on Scientific Evidence, third edition (RMSE 3d).  Much of what is covered is solid information on the individual scientific and technical disciplines covered.  Although the information is easily available from other sources, there is some value in collecting the material in a single volume for the convenience of judges.  Of course, given that this information is provided to judges from an ostensibly neutral, credible source, lawyers will naturally focus on what is doubtful or controversial in the RMSE.

I have already noted some preliminary concerns, however, with some of the comments in the Preface, by Judge Kessler and Dr. Kassirer.  See “New Reference Manual’s Uneven Treatment of Conflicts of Interest.”  In addition, there is a good deal of overlap among the chapters on statistics, epidemiology, and medical testimony.  This overlap is at first blush troubling because the RMSE has the potential to confuse and obscure issues by having multiple authors address them inconsistently.  This is an area where reviewers should pay close attention.

From first looks at the RMSE 3d, there is a good deal of equivocation between encouraging judges to look at scientific validity, and discouraging them any meaningful analysis by emphasizing inaccurate proxies for validity, such as conflicts of interest.  (As I have pointed out, the new RSME did not do quite so well in addressing its own conflicts of interest.  See “Toxicology for Judges – The New Reference Manual on Scientific Evidence (2011).”) The strengths of the chapter on statistical evidence, updated from the second edition, remain, as do some of the strengths and flaws of the chapter on epidemiology.  I hope to write more about each of these important chapters at a later date.

The late Professor Margaret Berger has an updated version of her chapter from the second edition, “The Admissibility of Expert Testimony,” RSME 3d 11 (2011).  Berger’s chapter has a section criticizing “atomization,” a process she describes pejoratively as a “slicing-and-dicing” approach.  Id. at 19.  Drawing on the publications of Daubert-critic Susan Haack, Berger rejects the notion that courts should examine the reliability of each study independently. Id. at 20 & n. 51 (citing Susan Haack, “An Epistemologist in the Bramble-Bush: At the Supreme Court with Mr. Joiner,” 26 J. Health Pol. Pol’y & L. 217–37 (1999).  Berger contends that the “proper” scientific method, as evidenced by works of the International Agency for Research on Cancer, the Institute of Medicine, the National Institute of Health, the National Research Council, and the National Institute for Environmental Health Sciences, “is to consider all the relevant available scientific evidence, taken as a whole, to determine which conclusion or hypothesis regarding a causal claim is best supported by the body of evidence.” Id. at 19-20 & n.52.  This contention, however, is profoundly misleading.  Of course, scientists undertaking a systematic review should identify all the relevant studies, but some of the “relevant” studies may well be insufficiently reliable (because of internal or external validity issues) to answer the research question at hand. All the cited agencies, and other research organizations and researchers, exclude studies that are fundamentally flawed, whether as a result of bias, confounding, erroneous data analyses, or related problems.  Berger cites no support for the remarkable suggestion that scientists do not make “reliability” judgments about available studies when assessing the “totality of the evidence.”

Professor Berger, who had a distinguished career as a law professor and evidence scholar, died in November 2010.  She was no friend of Daubert, but remarkably her antipathy has outlived her.  Her critical discussion of “atomization” cites the notorious decision in Milward v. Acuity Specialty Products Group, Inc., 639 F.3d 11, 26 (1st Cir. 2011), which was decided four months after her passing. Id. at 20 n.51. (The editors note that the published chapter was Berger’s last revision, with “a few edits to respond to suggestions by reviewers.”)

Professor Berger’s contention about the need to avoid assessments of individual studies in favor of the whole gamish must also be rejected because Federal Rule of Evidence 703 requires that each study considered by an expert witness “qualify” for reasonable reliance by virtue of the study’s containing facts or data that are “of a type reasonably relied upon by experts in the particular field forming opinions or inferences upon the subject.”  One of the deeply troubling aspects of the Milward decision is that it reversed the trial court’s sensible decision to exclude a toxicologist, Dr. Martyn Smith, who outran his headlights on issues having to do with a field in which he was clearly inexperienced – epidemiology.

Scientific studies, and especially epidemiologic studies, involve multiple levels of hearsay.  A typical epidemiologic study may contain hearsay leaps from patient to clinician, to laboratory technicians, to specialists interpreting test results, back to the clinician for a diagnosis, to a nosologist for disease coding, to a national or hospital database, to a researcher querying the database, to a statistician analyzing the data, to a manuscript that details data, analyses, and results, to editors and peer reviewers, back to study authors, and on to publication.  Those leaps do not mean that the final results are untrustworthy, only that the study itself is not likely admissible in evidence.

The inadmissibility of scientific studies is not problematic because Rule 703 permits testifying expert witnesses to formulate opinions based upon facts and data, which are not themselves admissible in evidence. The distinction between relied upon, and admissible, studies is codified in the Federal Rules of Evidence, and in virtually every state’s evidence law.

Referring to studies, without qualification, as admissible in themselves is wrong as a matter of evidence law.  The error has the potential to encourage carelessness in gatekeeping expert witnesses’ opinions for their reliance upon inadmissible studies.  The error is doubly wrong if this approach to expert witness gatekeeping is taken as license to permit expert witnesses to rely upon any marginally relevant study of their choosing.  It is therefore disconcerting that the new Reference Manual on Science Evidence (RMSE 3d) fails to make the appropriate distinction between admissibility of studies and admissibility of expert witness opinion that has reasonably relied upon appropriate studies.

Consider the following statement from the chapter on epidemiology:

“An epidemiologic study that is sufficiently rigorous to justify a conclusion that it is scientifically valid should be admissible,184 as it tends to make an issue in dispute more or less likely.185"

RMSE 3d at 610.  Curiously, the authors of this chapter have ignored Professor Berger’s caution against slicing and dicing, and speak to a single study’s ability to justify a conclusion. The authors of the epidemiology chapter seem to be stressing that scientifically valid studies should be admissible.  The footnote emphasizes the point:

See DeLuca v. Merrell Dow Pharms., Inc., 911 F.2d 941, 958 (3d Cir. 1990); cf. Kehm v. Procter & Gamble Co., 580 F. Supp. 890, 902 (N.D. Iowa 1982) (“These [epidemiologic] studies were highly probative on the issue of causation—they all concluded that an association between tampon use and menstrually related TSS [toxic shock syndrome] cases exists.”), aff’d, 724 F.2d 613 (8th Cir. 1984). Hearsay concerns may limit the independent admissibility of the study, but the study could be relied on by an expert in forming an opinion and may be admissible pursuant to Fed. R. Evid. 703 as part of the underlying facts or data relied on by the expert. In Ellis v. International Playtex, Inc., 745 F.2d 292, 303 (4th Cir. 1984), the court concluded that certain epidemiologic studies were admissible despite criticism of the methodology used in the studies. The court held that the claims of bias went to the studies’ weight rather than their admissibility. Cf. Christophersen v. Allied-Signal Corp., 939 F.2d 1106, 1109 (5th Cir. 1991) (“As a general rule, questions relating to the bases and sources of an expert’s opinion affect the weight to be assigned that opinion rather than its admissibility. . . .”).”

RMSE 3d at 610 n.184 (emphasis in bold, added).  This statement, that studies relied upon by an expert in forming an opinion may be admissible pursuant to Rule 703, is unsupported by Rule 703 and the overwhelming weight of case law interpreting and applying the rule.  (Interestingly, the authors of this chapter seem to abandon their suggestion that studies relied upon “might qualify for the learned treatise exception to the hearsay rule, Fed. R. Evid. 803(18), or possibly the catchall exceptions, Fed. R. Evid. 803(24) & 804(5),” which was part of their argument in the Second Edition of the RMSE.  RMSE 2d at 335 (2000).)  See also RMSE 3d at 214 (discussing statistical studies as generally “admissible,” but acknowledging that admissibility may be no more than permission to explain the basis for an expert’s opinion).

The cases cited by the epidemiology chapter, Kehm and Ellis, both involved “factual findings” in public investigative or evaluative reports, which were independently admissible under Federal Rule of Evidence 803(8)(C).  See Ellis, 745 F.2d at 299-303; Kehm, 724 F.2d at 617-18.  As such, the cases hardly support the chapter’s suggestion that Rule 703 is a rule of admissibility for epidemiologic studies.

Here the RMSE, in one sentence, confuses Rule 703 with an exception to the rule against hearsay, which would prevent the statistical studies from being received in evidence.  The point is reasonably clear, however, that the studies “may be offered” to explain an expert witness’s opinion.  Under Rule 705, that offer may also be refused. The offer, however, is to “explain,” not to have the studies admitted in evidence.

The RMSE is certainly not alone in advancing this notion that studies are themselves admissible.  Other well-respected evidence scholars lapse into this position:

“Well conducted studies are uniformly admitted.”

David L. Faigman, et al., Modern Scientific Evidence:  The Law and Science of Expert Testimony v.1, § 23:1,at 206 (2009)

Evidence scholars should not conflate admissibility of the epidemiologic (or other) studies with the ability of an expert witness to advert to a study to explain his or her opinion.  The testifying expert witness really has no need to become a conduit for off-hand comments and opinions in the introduction or discussion section of relied upon articles, and the wholesale admission of such hearsay opinions undermines the court’s control over opinion evidence.  Rule 703 authorizes reasonable reliance upon “facts and data,” not every opinion that creeps into the published literature.

Nathan Schachtman is in private practice in New York City, and is a lecturer-in-law at the Columbia University Law School.

Bookmark and Share

 

(originally posted on www.masstortsstateoftheart.com on October 4, 2011)

Well, the Reference Manual on Scientific Evidence: Third Edition is out. And the fix is in.
Think we exaggerate? How about this little gem from the Preface: "Judges and juries, however, must consider financial conflicts of interest when assessing scientific testimony. The threshold for pursuing the possibility of bias must be low. In some instances, judges have been frustrated in identifying expert witnesses who are free of conflict of interest because entire fields of science seem to be co-opted by payments from industry"?

Or how about the first section of the first chapter of the Manual: "A. Atomization"? Citing our least favorite case, Milward v. Acuity, the Manual frowns on the effort of courts to examine the premises, and the evidence allegedly supporting those premises, of an expert when determining whether his causal inference is warranted. Noting, very slyly and without disclosing their demand for transparency and accountability, that certain well known and respected authorities have concluded that ultimately the determination of causation is a matter of scientific judgment "reflecting the weight of the evidence", the Manual chastises those who might cock an eyebrow when it turns out that none of the "evidence" proffered by an expert actually supports his opinion. What duties would be left to a gatekeeper obliged to accept the mere ipse dixit of a well credentialed academic? The Manual, unsurprisingly, doesn't say.

Worse yet, and indicative of who, and what cause, was behind the effort, the Manual goes on to cite the new-ish Milward three more times. Once for the proposition that the unproveability of a theory is proof of the theory; once to support the rubber stamping of an expert's personalized and unexamined - weighing in the scales of his scientific judgment - "methodology"; and, once to reject the idea that statistical significance testing - the "it might be so" hurdle for hypothesis generation from statistics - is any business of federal judges.

The first chapter tellingly concludes that "there are serious concerns about whether ... the guidelines have resulted in trial judges encroaching on the province of the jury to ... judge the overall credibility of  ... scientific theories." We thought the whole point of Daubert was to ensure a better approximation of the truth by at least limiting the theories to be considered by lay juries to those that have a decent chance of being true. Guess not.

David Oliver is managing partner of the Houston office of Vorys, Sater, Seymour and Pease. His practice focuses on civil litigation involving allegations of injuries due to exposure to chemicals or pharmaceuticals; he holds degrees in both chemistry and biology. David is registered for DRI’s Annual Meeting. He is speaking at the Toxic Tort Committee CLE session on October 28.  

Bookmark and Share

 

Investigating An Auto Accident Case

Posted on March 15, 2010 08:37 by Francisco Ramos Jr

With advances in technology, there is more and more information out there relevant to your auto case. Some of the following may help you build your case or undermine your opponent’s:

Sun Pass. Based on the tolls paid, you can find out where a vehicle was on the day it was involved in the accident.

Cell records: Was the driver on the phone at the time of the accident? Who was he talking to? After the accident, whom did he call? He may have made admissions about the accident.

Text messages and e-mails: Instead of calling someone, the driver may have been sending a text message or an e-mail. Being on the phone is distracting. Typing on your phone is so much more distracting.

Traffic reports: Reports reflecting lane closures or accidents may give an indication of the flow of traffic at the time of an auto accident. The traffic conditions may make a claim of a speeding vehicle preposterous.

Video footage: There may be footage of the accident, particularly if it happened during rush hour, where the traffic helicopter may have caught your accident on video.

Black box. Some vehicles have "black boxes" that preserve information at the time of the accident, such as the speed of the vehicle. The parties can enter into an agreement to secure the black boxes from the vehicles involved in the accident and have them analyzed by mutually agreed upon experts.

Aerial shots: An aerial shot of the accident scene may prove helpful. Google Earth is a good source for such a photograph.

GPS. Were the drivers using GPS, such as Garmin or Magellan? Were they using an online service like Onstar? There may be information about the driver’s route.


The police report is a good start when investigating a car accident case, but it is only a start. There are so many other avenues to pursue when investigating who caused the accident.

Francisco Ramos is a partner at Clarke Silverglate Campbell in Miami where he can be reached at framos@csclawfirm.com or 305.347.1544.

Bookmark and Share

Categories: Evidence

Actions: E-mail | Comments

 
 

Submit Blog

If you wish to submit a blog posting for DRI Today, send an email to today@dri.org with "Blog Post" in the subject line. Please include article title and any tags you would like to use for the post.
 
DRI President's Blog
 
 

Search Blog


Recent Posts

Categories

Authors

Blogroll



Staff Login